Immunology Trials

Is rituximab noninferior to ocrelizumab for suppressing MRI-detected disease activity in newly diagnosed relapsing multiple sclerosis?

Does a bodyweight-adjusted higher dose of ocrelizumab provide better disability progression control than the approved 600 mg dose in relapsing or primary progressive multiple sclerosis?

Does ocrelizumab delay disability progression — particularly loss of hand function — in a broad PPMS population that includes older patients and those with more advanced disability typically excluded from registration trials?

Does a long-acting once-monthly intramuscular glatiramer acetate (GA Depot) reduce relapses and MRI activity compared with placebo in relapsing multiple sclerosis?

Do treatment effects on neurofilament light chain track with treatment effects on clinical and MRI endpoints well enough for NfL to serve as a surrogate marker of disease activity in MS?

In a multicenter international cohort of 103 patients with DS-NMOSD, anti-CD20 therapy (mostly rituximab) was associated with a ~98% lower relapse incidence rate ratio than the pretreatment period and...

Opicinumab 750 mg IV q4w did not meet its primary endpoint (Overall Disability Response Score) at 72 weeks, although a multicomponent CDI endpoint that incorporated SDMT and a prespecified subgroup wi...

In a real-world cohort of 176 patients with NMOSD followed for a median of 9 years, FDA-approved NMOSD-specific therapies (C5 inhibitors, inebilizumab, satralizumab) were substantially more effective ...